| ULTRAGENYX PHARM. DL-,001 |
| USA |
| Gesundheit |
| US90400D1081 / A1XCY0 |
| UP0 (Frankfurt) / RARE (NASDAQ) |
| FRA:UP0, ETR:UP0, UP0:GR, NASDAQ:RARE |
| - |
| https://www.ultragenyx.co.. |
|
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Ultragenyx Pharmaceutical Inc. currently markets medicines for conditions such as X-linked hyp..
>Volltext.. |
| 2136.99 Mio. EUR |
| 2815.97 Mio. EUR |
| 580.54 Mio. EUR |
| -457.69 Mio. EUR |
| -528.45 Mio. EUR |
| -5.3 EUR |
| 1040.66 Mio. EUR |
| 158.7 Mio. EUR |
| -430.59 Mio. EUR |
| 1.3 |
| 6.12% |
| -3.82% |
| - |
| - |
| - |
| ULTRAGENYX |
| 05.08.26 |